TENX insider transaction filings
TENAX THERAPEUTICS, INC. — 24 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-14. Screen TENX transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-14 | 4 | Giordano Christopher Thomas — CEO, Director | Option exercise (M): 219 @ $3.55 · Option exercise (M): 8,500 @ $5.94 · Option exercise (M): 219 (derivative) @ $0 · Option exercise (M): 8,500 (derivative) @ $0 | EDGAR |
| 2026-05-13 | 4 | STAAB THOMAS R II — Chief Financial Officer | Grant/award (A): 10,000 @ $0 · Grant/award (A): 450,000 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | MCGAULEY THOMAS — Interim CFO | Option exercise (M): 50,000 (derivative) @ $0 | EDGAR |
| 2026-01-13 | 4 | Giordano Christopher Thomas — CEO, Director | Grant/award (A): 450,000 (derivative) @ $0 | EDGAR |
| 2026-01-13 | 4 | Rich Stuart — Chief Medical Officer, Director | Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2026-01-13 | 4 | Hunter Robyn — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-01-13 | 4 | Doogan Declan — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-01-13 | 4 | Davidson Michael H. — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-01-13 | 4 | Almenoff June Sherie — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-01-13 | 4 | PROEHL GERALD T — Director | Grant/award (A): 3,000 (derivative) @ $0 | EDGAR |
| 2025-12-10 | 4 | Rich Stuart — Chief Medical Officer, Director | Purchase (P): 2,500 @ $10.10 · Purchase (P): 2,500 @ $10.22 | EDGAR |
| 2025-12-05 | 4 | Rich Stuart — Chief Medical Officer, Director | Purchase (P): 1,000 @ $9.01 · Purchase (P): 1,500 @ $9.08 · Purchase (P): 2,500 @ $9.20 | EDGAR |
| 2025-11-20 | 4 | Giordano Christopher Thomas — CEO, Director | Purchase (P): 1,612 @ $7.75 · Purchase (P): 455 @ $7.51 · Purchase (P): 538 @ $7.59 | EDGAR |
| 2025-11-20 | 4/A | Almenoff June Sherie — Director | Purchase (P): 93 @ $7.15 · Purchase (P): 1,900 @ $7.52 | EDGAR |
| 2025-11-19 | 4 | MCGAULEY THOMAS — Interim CFO | Purchase (P): 2,000 @ $7.34 · Purchase (P): 1,000 @ $7.35 · Purchase (P): 5,000 @ $7.23 | EDGAR |
| 2025-11-19 | 4 | Almenoff June Sherie — Director | Purchase (P): 93 @ $7.15 · Purchase (P): 1,900 @ $7.52 | EDGAR |
| 2025-07-03 | 4 | Hunter Robyn — Director | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2025-07-03 | 4 | Doogan Declan — Director | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2025-07-03 | 4 | Davidson Michael H. — Director | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2025-07-03 | 4 | Almenoff June Sherie — Director | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2025-07-03 | 4 | PROEHL GERALD T — Director | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2025-05-20 | 4 | Giordano Christopher Thomas — CEO, Director | Grant/award (A): 1,400,000 (derivative) @ $0 | EDGAR |
| 2025-05-20 | 4 | Rich Stuart — Chief Medical Officer, Director | Grant/award (A): 625,000 (derivative) @ $0 | EDGAR |
| 2025-03-12 | 4 | Dellora Investments LP | Holdings only — no transactions reported | EDGAR |
Recent 8-K events — TENAX THERAPEUTICS, INC.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-10 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-31 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-02 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-30 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-29 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-04 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-22 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-09 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=TENX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →